(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 88.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.08%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Syndax Pharmaceuticals's revenue in 2025 is $78,180,000.On average, 16 Wall Street analysts forecast SNDX's revenue for 2025 to be $14,888,759,428, with the lowest SNDX revenue forecast at $12,860,979,997, and the highest SNDX revenue forecast at $17,547,958,708. On average, 16 Wall Street analysts forecast SNDX's revenue for 2026 to be $31,971,552,081, with the lowest SNDX revenue forecast at $14,157,415,020, and the highest SNDX revenue forecast at $42,915,875,648.
In 2027, SNDX is forecast to generate $44,437,140,931 in revenue, with the lowest revenue forecast at $19,492,180,533 and the highest revenue forecast at $65,589,275,145.